Quent Capital LLC Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Quent Capital LLC increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 918 shares of the medical equipment provider’s stock after acquiring an additional 42 shares during the period. Quent Capital LLC’s holdings in Intuitive Surgical were worth $314,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. MONECO Advisors LLC boosted its stake in shares of Intuitive Surgical by 3.5% during the 1st quarter. MONECO Advisors LLC now owns 964 shares of the medical equipment provider’s stock worth $246,000 after acquiring an additional 33 shares in the last quarter. Patron Partners LLC raised its position in shares of Intuitive Surgical by 2.3% during the 1st quarter. Patron Partners LLC now owns 1,481 shares of the medical equipment provider’s stock worth $378,000 after purchasing an additional 34 shares during the last quarter. Forum Financial Management LP raised its position in shares of Intuitive Surgical by 1.9% during the 1st quarter. Forum Financial Management LP now owns 1,927 shares of the medical equipment provider’s stock worth $492,000 after purchasing an additional 36 shares during the last quarter. Arlington Partners LLC raised its position in shares of Intuitive Surgical by 14.3% during the 1st quarter. Arlington Partners LLC now owns 288 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 36 shares during the last quarter. Finally, Covenant Asset Management LLC raised its position in shares of Intuitive Surgical by 1.8% during the 1st quarter. Covenant Asset Management LLC now owns 2,057 shares of the medical equipment provider’s stock worth $526,000 after purchasing an additional 36 shares during the last quarter. 82.91% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 2.7 %

ISRG stock opened at $295.54 on Friday. The company has a market cap of $103.85 billion, a price-to-earnings ratio of 74.07, a PEG ratio of 4.25 and a beta of 1.30. The business has a fifty day simple moving average of $314.56 and a 200-day simple moving average of $297.57. Intuitive Surgical, Inc. has a 52 week low of $180.07 and a 52 week high of $358.07.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 20th. The medical equipment provider reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.09. Intuitive Surgical had a net margin of 21.38% and a return on equity of 12.41%. The firm had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.74 billion. During the same period in the prior year, the company earned $0.85 EPS. The firm’s revenue was up 15.4% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical, Inc. will post 4.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Barclays lifted their price objective on Intuitive Surgical from $314.00 to $385.00 and gave the stock an “overweight” rating in a research report on Monday, July 24th. Royal Bank of Canada restated an “outperform” rating and set a $360.00 price objective on shares of Intuitive Surgical in a research report on Thursday, August 17th. Truist Financial lifted their price objective on Intuitive Surgical from $347.00 to $400.00 in a research report on Wednesday, July 19th. Citigroup boosted their price target on Intuitive Surgical from $317.00 to $400.00 in a report on Monday, July 10th. Finally, Sanford C. Bernstein boosted their price target on Intuitive Surgical from $350.00 to $365.00 in a report on Wednesday, May 31st. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $343.10.

Insider Buying and Selling

In related news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $310.00, for a total transaction of $620,000.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $7,848,890. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 2,535 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $323.26, for a total value of $819,464.10. Following the completion of the transaction, the executive vice president now directly owns 7,259 shares of the company’s stock, valued at approximately $2,346,544.34. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $310.00, for a total transaction of $620,000.00. Following the completion of the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at $7,848,890. The disclosure for this sale can be found here. In the last three months, insiders sold 60,309 shares of company stock valued at $19,649,321. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.